BackAmbrx Biopharma Overview

Ambrx Biopharma Minority Interest

Track Ambrx Biopharma's minority interest ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

Ambrx Biopharma Minority Interest History

Loading

Ambrx Biopharma vs. peers: Minority Interest Comparison

Loading

Ambrx Biopharma Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ambrx Biopharma (AMAM) FAQ

As of the most recent data (September 2023), AMAM shows a minority interest of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMAM's minority interest is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Ambrx Biopharma is outperforming or lagging.

Tracking AMAM's minority interest over time shows whether Ambrx Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this minority interest page, Stockcircle has Ambrx Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect minority interest (currently $0) with ownership activity and broader fundamentals.

Ambrx Biopharma's minority interest is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.